X

Trial Profile

A phase 2 study of bitopertin for treatment of the erythropoietic porphyrias (EP)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bitopertin (Primary)
Indications Erythropoietic porphyria
Focus Therapeutic Use

Most Recent Events

08 Nov 2024 According to Disc Medicine media release, the company has obtained a $200 million non-dilutive term loan facility from Hercules Capital, which will support potential initiation of a confirmatory trial of bitopertin in erythropoietic protoporphyria (EPP) by mid-2025, along with other studies.
02 Jun 2021 New trial record
27 May 2021 According to a Disc Medicine media release, the company expects to start this study in 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com